Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Serious adverse events Up to 12 weeks' · Patients with acute low‐back pain

Paracetamol showed no clear difference in serious adverse events Up to 12 weeks' compared with placebo (moderate certainty).

1 finding from 1 review

Paracetamol for low back pain 2016 · Cochrane Headline outcomes only
RR 0.9 [0.3, 2.67]
1 study · 1643 participants
Moderate

Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)

Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.99 [0.39, 2.5]
1 study · 155 participants
Low